choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Actemra

Actemra Newsletter
  • FDA Issues CRL to Odronextamab in Pretreated Follicular Lymphoma 04 Aug 2025 20:59 GMT

    … phase 2 ELM-2 trials (NCT03888105) provided context … Updated results from the trial were shared at the … steroids (33.3%), tocilizumab (Actemra; 16.7%), and both … treatment of relapsed/refractory follicular lymphoma. News release. Regeneron Pharmaceuticals …

  • Expert: FDA-Approved Linvoseltamab Delivers Deep Responses, Offering New Hope For Older Patients With MM 24 Jul 2025 21:06 GMT

    … , MBBS, professor of medicine—hematology and oncology at Mount … antibody approved for the treatment of relapsed or refractory … In the trial, investigators could use tocilizumab (Actemra; Genentech) or … grades. Now that the drug is commercially available, people …

  • Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma 04 Aug 2025 20:59 GMT

    … now, and some clinical trials that we believe will … starting to use drugs like tocilizumab [Actemra] as a cytokine … potential impact for administering the treatment outpatient and [among] … shots and administering other medications that help their cytopenia. …

  • FDA Eases Access to CAR-T Therapies 10 Jul 2025 19:04 GMT

    … drugs, such as tocilizumab (Actemra), and corticosteroids. To mitigate this risk, the FDA … burden on patients seeking transformative treatments for deadly blood cancers,” Stephen … of the Alliance for Regenerative Medicine, told BioSpace. Information about CAR …

  • Blockbuster Novartis Drug Fails Key Test Hoped to Expand Its Use to Rare Blood Vessel Disorder 06 Jul 2025 16:41 GMT

    … disorders. Roche’s Actemra already enables steroid tapering … arm. On secondary trial goals measuring cumulative … diseases,” Novartis Chief Medical Officer Shreeram Aradhye said … treatment of plaque psoriasis. Since then, the drug has landed additional FDA …

  • Novartis’ Cosentyx shows no benefit in Phase III GCA trial 04 Jul 2025 16:06 GMT

    … countries. Novartis’ chief medical officer Dr Shreeram Aradhye, … treatment. Patients may also be treated with Actemra (tocilizumab … and Drug Administration (FDA) in January 2015 for the treatment … industry insights. Clinical Trials Arena Excellence Awards - …

  • Novartis drug flunks phase 3 test in giant cell arteritis 03 Jul 2025 12:53 GMT

    … warrant additional testing of the drug in GCA. While disappointing for … are already approved by the FDA for GCA. In 2017, … ;s anti-IL-6 antibody Actemra (tocilizumab) was approved for adults … treatment for the disorder based on results of the SELECT-GCA trial …

  • FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma 02 Jul 2025 19:31 GMT

    … escalation portion of the trial investigated linvoseltamab’s safety … Actemra; Genentech) to treat CRS.1,4,5 The FDA … Standard of Care Treatments. National Library of Medicine. ClinicalTrials.gov … Multiple Myeloma. Applied Clinical Trials. Published June 17, 2024 …

  • FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS 01 Jul 2025 02:55 GMT

    … Janssen Biotech, Inc) Tisagenlecleucel (Kymriah; Novartis Pharmaceuticals Corporation) … access to tocilizumab (Actemra; Genentech). Patients are … treatments while continuing to prioritize safety.” References FDA … ;/www.fda.gov/vaccines-blood-biologics…

  • FDA Removes REMS for Currently Approved BCMA-, CD19-Directed CAR T Cell Immunotherapies 30 Jun 2025 21:34 GMT

    … delivery of potentially curative treatments to patients and … to ensure drug safety in certain medications with serious … site access to tocilizumab (Actemra; Genentech), which is … treatments while continuing to prioritize safety.”1 REFERENCES 1. FDA. FDA …

Satisfied with the content?

Continue to create your account.